Published : Oct 2019
Tables : 71
Figures : 44
Category : Healthcare
No. of Pages : 151
Report Code : HC-1218
The global cardiac biomarker diagnostic kits market is poised to reach USD 4.5 billion by 2026 end and achieve a CAGR of over 7% from the forecast period 2019-2026. Factors such as increasing geriatric population and increasing cases of cardiovascular diseases are increasing the cardiac biomarker diagnostic kits market size. Current clinical trials for identification of novel cardiac biomarkers coupled with increasing fund from public-private organizations for research and development is also expanding the market. The market is bifurcated into by type, by product, by disease, by type of testing and by region. The troponin I and T segment are expected to show notable cardiac biomarker diagnostic kits market growth owing to its high sensitivity, rapid prediction of outcomes and high specificity. It also offers longer elevation time. All these benefits have resulted in demand for troponin I and T, thus proliferating the market. Based on product, reagents and kits are expected to dominate the growth of the market. Increasing cases of cardiovascular diseases and the availability of multiple reagents ad kits is driving the growth of the market. In addition, the continuous launch of reliable, faster and new reagents and kits increasing the cardiac biomarker diagnostic kits size. On the basis of the type of testing, point-of-care testing is expected to control the growth of the market. Point-of-care testing offers various benefits such as enhanced user and patient experience, reduced length of stay and better turnaround times. All these benefits have resulted in rising point-of-care testing procedures. Technological advancements have led in much faster, advances and easy to use devices, thus resulting in expansion of the market. In terms of disease, myocardial infarction segment is expected to control the growth of the market. The increasing number of patients required for the diagnosis of acute myocardial infarction remains the major factor boosting the growth of the market. In terms of region, North America is the global front runner of the market. The rise in geriatric population coupled with presence of prominent players is bolstering the market in the region. The increasing incidence of cardiovascular disease coupled with rising adoption of point-of-care diagnostic is expected to accelerate the growth of the market in the region. Prominent players of the market are bioMerieux SA, Guangzhou Wondfo Biotech Co., Ltd, Danaher Corporation, Siemens AG, Abbott Laboratories, Alere, Inc., LSI Medience Corporation, Randox laboratories, and Ortho Clinical Diagnostics. Competitive Landscape: Abbott in 2017 acquired Alere. The acquisition helped in bolstering the company's portfolio Global Cardiac Biomarker Diagnostic Kits Market Segmentation By Type Troponin I and T CK-MB Bnp Or Nt-Probnp Myoglobin Hscrp Other Biomarkers By Product Reagents and Kits Instruments Chemiluminescence Immunofluorescence Elisa Immunochromatography By Disease Myocardial Infarction Congestive Heart Failure By Type of Testing Laboratory Testing Point-Of-Care Testing By Region North America Europe Asia Pacific Latin America Rest of the World FutureWise Key Takeaways: Growth Prospects SWOT Analysis Key Trends Key data-points affecting market growth Objectives of the Study: To provide with an exhaustive analysis on the global cardiac biomarker diagnostic kits market by type, by product, by disease, by type of testing and by region To cater comprehensive information on factors impacting market growth (drivers, restraints, industry-specific restraints and opportunities) To forecast and evaluate micro-markets and the overall market To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and the rest of the world To record, evaluate and analyse competitive landscape mapping- technological advancements, product launches, expansions and mergers
The global cardiac biomarker diagnostic kits market is poised to reach USD 4.5 billion by 2026 end and achieve a CAGR of over 7% from the forecast period 2019-2026.
Factors such as increasing geriatric population and increasing cases of cardiovascular diseases are increasing the cardiac biomarker diagnostic kits market size. Current clinical trials for identification of novel cardiac biomarkers coupled with increasing fund from public-private organizations for research and development is also expanding the market.
The market is bifurcated into by type, by product, by disease, by type of testing and by region. The troponin I and T segment are expected to show notable cardiac biomarker diagnostic kits market growth owing to its high sensitivity, rapid prediction of outcomes and high specificity. It also offers longer elevation time. All these benefits have resulted in demand for troponin I and T, thus proliferating the market.
Based on product, reagents and kits are expected to dominate the growth of the market. Increasing cases of cardiovascular diseases and the availability of multiple reagents ad kits is driving the growth of the market. In addition, the continuous launch of reliable, faster and new reagents and kits increasing the cardiac biomarker diagnostic kits size.
On the basis of the type of testing, point-of-care testing is expected to control the growth of the market. Point-of-care testing offers various benefits such as enhanced user and patient experience, reduced length of stay and better turnaround times. All these benefits have resulted in rising point-of-care testing procedures. Technological advancements have led in much faster, advances and easy to use devices, thus resulting in expansion of the market.
In terms of disease, myocardial infarction segment is expected to control the growth of the market. The increasing number of patients required for the diagnosis of acute myocardial infarction remains the major factor boosting the growth of the market.
In terms of region, North America is the global front runner of the market. The rise in geriatric population coupled with presence of prominent players is bolstering the market in the region. The increasing incidence of cardiovascular disease coupled with rising adoption of point-of-care diagnostic is expected to accelerate the growth of the market in the region.
Prominent players of the market are bioMerieux SA, Guangzhou Wondfo Biotech Co., Ltd, Danaher Corporation, Siemens AG, Abbott Laboratories, Alere, Inc., LSI Medience Corporation, Randox laboratories, and Ortho Clinical Diagnostics.
Competitive Landscape:
Global Cardiac Biomarker Diagnostic Kits Market Segmentation
By Type
By Product
By Disease
By Type of Testing
By Region
FutureWise Key Takeaways:
Objectives of the Study:
1 Introduction 1.1 Objectives of the Study 1.2 Market Definition 1.3 Markets Covered 1.3.1 Years Considered for the Study 1.4 Currency 1.5 Limitations 1.6 Stakeholders 2 Research Methodology 2.1 Research Methodology Steps 2.2 Secondary and Primary Research Methodology 2.2.1 Secondary Research 2.2.1.1 Key Data From Secondary Sources 2.2.2 Primary Research 2.2.2.1 Breakdown of Primaries 2.2.2.2 Key Data From Primary Sources 2.3 Market Size Estimation 2.3.1 Research Methodology: Bottom-Up Approach 2.3.2 Research Methodology: Top-Down Approach 2.4 Market Breakdown and Data Triangulation 3 Executive Summary 3.1 Introduction 3.2 Evolution 3.3 Current Scenario 3.4 Future Outlook 3.5 Conclusion 4 Premium Insights 4.1 Global Cardiac Marker Testing Market Overview 4.2 Geographic Analysis: Cardiac Marker Testing Market, By Technology, 2016 4.3 Market Size, By Type, 2016 vs 2021 4.4 Market, By Product, 2016 vs 2021 4.5 Geographical Snapshot of the Market, 2016 4.6 Life Cycle Analysis, By Region 5 Market Overview 5.1 Introduction 5.2 Market Dynamics 5.2.1 Drivers 5.2.1.1 Growing Incidences of Cardiovascular Diseases 5.2.1.2 Rapidly Increasing Geriatric Population and the Subsequent Increase in the Burden of Heart Diseases Worldwide 5.2.1.3 Growing Funding From Public–Private Organizations for Research on Cardiac Biomarkers 5.2.1.4 Ongoing Clinical Trials for Identification of Novel Cardiac Biomarkers 5.2.2 Restraints 5.2.2.1 Technical Problems Related to Sample Collection and Storage 5.2.2.2 Issues Related to Regulatory and Reimbursement Systems 5.2.3 Opportunities 5.2.3.1 Point-Of-Care Testing (Poct) With Cardiac Biomarkers 5.2.3.2 Emerging Markets to Offer New Growth Avenues for Market Players 6 Industry Insights 6.1 Introduction 6.2 Value Chain Analysis 6.3 Industry Trends 6.3.1 Ongoing Research on Novel Cardiac Biomarkers for Cardiovascular Diseases 6.3.2 Combination of Various Cardiac Biomarkers to Improve Patient Management 6.3.3 Development of High-Sensitivity Troponin Assays 6.4 Porter’s Five Forces Analysis 6.4.1 Threat of New Entrants 6.4.2 Threat of Substitutes 6.4.3 Bargaining Power of Suppliers 6.4.4 Bargaining Power of Buyers 6.4.5 Intensity of Competitive Rivalry 7 Cardiac Marker Testing Market, By Type 7.1 Introduction 7.2 Troponin I and T 7.3 CK-MB 7.4 Bnp Or Nt-Probnp 7.5 Myoglobin 7.6 Hscrp 7.7 Other Biomarkers 8 Cardiac Marker Testing Market, By Product 8.1 Introduction 8.2 Reagents and Kits 8.3 Instruments 8.3.1 Chemiluminescence 8.3.2 Immunofluorescence 8.3.3 Elisa 8.3.4 Immunochromatography 9 Cardiac Marker Testing Market, By Disease 9.1 Introduction 9.2 Myocardial Infarction 9.3 Congestive Heart Failure 10 Cardiac Marker Testing Market, By Type of Testing 10.1 Introduction 10.2 Laboratory Testing 10.3 Point-Of-Care Testing 11 Cardiac Marker Testing Market, By Region 11.1 Introduction 11.2 North America 11.2.1 U.S. 11.2.1.1 Growing Prevalence of Cardiovascular Diseases 11.2.1.2 Increasing Public-Private Investments on Cardiac Biomarker Research 11.2.1.3 Rising Geriatric & Obese Population 11.2.1.4 Nih Support for the Development of Cardiac Biomarkers 11.2.2 Canada 11.2.2.1 Rising Incidence of Cardiovascular Diseases 11.2.2.2 Increasing Government Investments 11.3 Europe 11.3.1 Rising Incidence of CVD 11.3.2 Increasing Number of Conferences and Symposiums 11.3.3 Rising Partnerships and Collaborations for the Development of Cardiac Biomarkers 11.3.4 Increasing Government Investments to Develop Novel Cardiac Biomarkers 11.4 Asia-Pacific 11.4.1 Increasing Incidence of CVD 11.4.2 Increasing Awareness Due to Going Conferences and Initiatives Taken By Market Players 11.4.3 Government Investments Towards Cardiac Biomarker Research 11.5 Rest of the World 12 Competitive Landscape 12.1 Introduction 12.2 Strategic Overview 12.3 Leading Players in the Market 12.4 Competitive Situation and Trends 12.4.1 Product Launches, Approvals, and Showcases 12.4.2 Agreements and Partnerships 12.4.3 Acquisitions 12.4.4 Other Developments 13 Company Profiles (Overview, Products and Services, Financials, Strategy & Development)* 13.1 Introduction 13.2 Roche Diagnostics Limited (A Subsidiary of F. Hoffman-LA Roche Ltd.) 13.3 Abbott Laboratories 13.4 Siemens AG 13.5 Danaher Corporation 13.6 Biomérieux SA 13.7 Alere Inc. 13.8 LSI Medience Corporation (A Subsidiary 0f Mitsubishi Chemical Holdings Corporation) 13.9 Ortho Clinical Diagnostics (A Subsidiary of the Carlyle Group) 13.10 Randox Laboratories Ltd. 13.11 Guangzhou Wondfo Biotech Co., Ltd. Chapter 14 Research Finding and Conclusion Chapter 15 Research Methodology Chapter 16 Research Data Source
1 Introduction
1.1 Objectives of the Study
1.2 Market Definition
1.3 Markets Covered
1.3.1 Years Considered for the Study
1.4 Currency
1.5 Limitations
1.6 Stakeholders
2 Research Methodology
2.1 Research Methodology Steps
2.2 Secondary and Primary Research Methodology
2.2.1 Secondary Research
2.2.1.1 Key Data From Secondary Sources
2.2.2 Primary Research
2.2.2.1 Breakdown of Primaries
2.2.2.2 Key Data From Primary Sources
2.3 Market Size Estimation
2.3.1 Research Methodology: Bottom-Up Approach
2.3.2 Research Methodology: Top-Down Approach
2.4 Market Breakdown and Data Triangulation
3 Executive Summary
3.1 Introduction
3.2 Evolution
3.3 Current Scenario
3.4 Future Outlook
3.5 Conclusion
4 Premium Insights
4.1 Global Cardiac Marker Testing Market Overview
4.2 Geographic Analysis: Cardiac Marker Testing Market, By Technology, 2016
4.3 Market Size, By Type, 2016 vs 2021
4.4 Market, By Product, 2016 vs 2021
4.5 Geographical Snapshot of the Market, 2016
4.6 Life Cycle Analysis, By Region
5 Market Overview
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 Growing Incidences of Cardiovascular Diseases
5.2.1.2 Rapidly Increasing Geriatric Population and the Subsequent Increase in the Burden of Heart Diseases Worldwide
5.2.1.3 Growing Funding From Public–Private Organizations for Research on Cardiac Biomarkers
5.2.1.4 Ongoing Clinical Trials for Identification of Novel Cardiac Biomarkers
5.2.2 Restraints
5.2.2.1 Technical Problems Related to Sample Collection and Storage
5.2.2.2 Issues Related to Regulatory and Reimbursement Systems
5.2.3 Opportunities
5.2.3.1 Point-Of-Care Testing (Poct) With Cardiac Biomarkers
5.2.3.2 Emerging Markets to Offer New Growth Avenues for Market Players
6 Industry Insights
6.1 Introduction
6.2 Value Chain Analysis
6.3 Industry Trends
6.3.1 Ongoing Research on Novel Cardiac Biomarkers for Cardiovascular Diseases
6.3.2 Combination of Various Cardiac Biomarkers to Improve Patient Management
6.3.3 Development of High-Sensitivity Troponin Assays
6.4 Porter’s Five Forces Analysis
6.4.1 Threat of New Entrants
6.4.2 Threat of Substitutes
6.4.3 Bargaining Power of Suppliers
6.4.4 Bargaining Power of Buyers
6.4.5 Intensity of Competitive Rivalry
7 Cardiac Marker Testing Market, By Type
7.1 Introduction
7.2 Troponin I and T
7.3 CK-MB
7.4 Bnp Or Nt-Probnp
7.5 Myoglobin
7.6 Hscrp
7.7 Other Biomarkers
8 Cardiac Marker Testing Market, By Product
8.1 Introduction
8.2 Reagents and Kits
8.3 Instruments
8.3.1 Chemiluminescence
8.3.2 Immunofluorescence
8.3.3 Elisa
8.3.4 Immunochromatography
9 Cardiac Marker Testing Market, By Disease
9.1 Introduction
9.2 Myocardial Infarction
9.3 Congestive Heart Failure
10 Cardiac Marker Testing Market, By Type of Testing
10.1 Introduction
10.2 Laboratory Testing
10.3 Point-Of-Care Testing
11 Cardiac Marker Testing Market, By Region
11.1 Introduction
11.2 North America
11.2.1 U.S.
11.2.1.1 Growing Prevalence of Cardiovascular Diseases
11.2.1.2 Increasing Public-Private Investments on Cardiac Biomarker Research
11.2.1.3 Rising Geriatric & Obese Population
11.2.1.4 Nih Support for the Development of Cardiac Biomarkers
11.2.2 Canada
11.2.2.1 Rising Incidence of Cardiovascular Diseases
11.2.2.2 Increasing Government Investments
11.3 Europe
11.3.1 Rising Incidence of CVD
11.3.2 Increasing Number of Conferences and Symposiums
11.3.3 Rising Partnerships and Collaborations for the Development of Cardiac Biomarkers
11.3.4 Increasing Government Investments to Develop Novel Cardiac Biomarkers
11.4 Asia-Pacific
11.4.1 Increasing Incidence of CVD
11.4.2 Increasing Awareness Due to Going Conferences and Initiatives Taken By Market Players
11.4.3 Government Investments Towards Cardiac Biomarker Research
11.5 Rest of the World
12 Competitive Landscape
12.1 Introduction
12.2 Strategic Overview
12.3 Leading Players in the Market
12.4 Competitive Situation and Trends
12.4.1 Product Launches, Approvals, and Showcases
12.4.2 Agreements and Partnerships
12.4.3 Acquisitions
12.4.4 Other Developments
13 Company Profiles
(Overview, Products and Services, Financials, Strategy & Development)*
13.1 Introduction
13.2 Roche Diagnostics Limited (A Subsidiary of F. Hoffman-LA Roche Ltd.)
13.3 Abbott Laboratories
13.4 Siemens AG
13.5 Danaher Corporation
13.6 Biomérieux SA
13.7 Alere Inc.
13.8 LSI Medience Corporation (A Subsidiary 0f Mitsubishi Chemical Holdings Corporation)
13.9 Ortho Clinical Diagnostics (A Subsidiary of the Carlyle Group)
13.10 Randox Laboratories Ltd.
13.11 Guangzhou Wondfo Biotech Co., Ltd.
Chapter 14 Research Finding and Conclusion
Chapter 15 Research Methodology
Chapter 16 Research Data Source
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics